Toll Biotech

About Toll Biotech

Toll Biotech specializes in the research and development of small molecules targeting Toll-like receptors (TLRs) to create novel therapies for autoimmune diseases. By collaborating with leading institutions, the company addresses the unmet clinical needs in the treatment of these conditions through its advanced immunomodulation technology.

```xml <problem> Current treatments for autoimmune diseases often have limited efficacy or significant side effects. There remains an unmet need for therapies that can more precisely modulate the immune system to resolve inflammation without causing broad immunosuppression. </problem> <solution> Toll Biotech is developing small molecule drugs that target Toll-like receptors (TLRs) to treat autoimmune diseases. Their approach focuses on immunomodulation, aiming to fine-tune the immune response and resolve inflammation. By selectively targeting TLRs, Toll Biotech seeks to create therapies that offer improved efficacy and reduced side effects compared to existing treatments. </solution> <features> - Focus on small molecule therapeutics for autoimmune diseases. - Targets Toll-like receptors (TLRs) for immunomodulation. - Collaborations with institutions such as Tsinghua University and Peking Union Medical College Hospital. </features> <target_audience> The primary target audience includes patients suffering from autoimmune diseases, as well as healthcare providers specializing in immunology and autoimmune disorders. </target_audience> ```

What does Toll Biotech do?

Toll Biotech specializes in the research and development of small molecules targeting Toll-like receptors (TLRs) to create novel therapies for autoimmune diseases. By collaborating with leading institutions, the company addresses the unmet clinical needs in the treatment of these conditions through its advanced immunomodulation technology.

Where is Toll Biotech located?

Toll Biotech is based in Beijing, China.

When was Toll Biotech founded?

Toll Biotech was founded in 2020.

Location
Beijing, China
Founded
2020
0

Find Investable Startups and Competitors

Search thousands of startups using natural language

Start Searching

Toll Biotech

⚠️ AI-generated overview based on web search data – may contain errors, please verify information yourself! You can claim this account with your email domain to make edits.

Executive Summary

Toll Biotech specializes in the research and development of small molecules targeting Toll-like receptors (TLRs) to create novel therapies for autoimmune diseases. By collaborating with leading institutions, the company addresses the unmet clinical needs in the treatment of these conditions through its advanced immunomodulation technology.

toll-biotech.com
Founded 2020 – Beijing, China

Funding

No funding information available.

Team

No team information available.

Company Description

Problem

Current treatments for autoimmune diseases often have limited efficacy or significant side effects. There remains an unmet need for therapies that can more precisely modulate the immune system to resolve inflammation without causing broad immunosuppression.

Solution

Toll Biotech is developing small molecule drugs that target Toll-like receptors (TLRs) to treat autoimmune diseases. Their approach focuses on immunomodulation, aiming to fine-tune the immune response and resolve inflammation. By selectively targeting TLRs, Toll Biotech seeks to create therapies that offer improved efficacy and reduced side effects compared to existing treatments.

Features

Focus on small molecule therapeutics for autoimmune diseases.

Targets Toll-like receptors (TLRs) for immunomodulation.

Collaborations with institutions such as Tsinghua University and Peking Union Medical College Hospital.

Target Audience

The primary target audience includes patients suffering from autoimmune diseases, as well as healthcare providers specializing in immunology and autoimmune disorders.

Want to add first party data to your startup here or get your entry removed? You can edit it yourself by logging in with your company domain.